标题
Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
作者
关键词
-
出版物
Scientific Reports
Volume 11, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-05-26
DOI
10.1038/s41598-021-90497-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt
- (2020) Christian Gege et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery and optimization of new oxadiazole substituted thiazole RORγt inverse agonists through a bioisosteric amide replacement approach
- (2020) Christoph Steeneck et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Secukinumab: A Review in Ankylosing Spondylitis
- (2019) Hannah A. Blair DRUGS
- 3-Substituted Quinolines as RORγt Inverse Agonists
- (2019) Virginia M. Tanis et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- (Inverse) Agonists of Retinoic Acid–Related Orphan Receptor γ: Regulation of Immune Responses, Inflammation, and Autoimmune Disease
- (2019) Anton M. Jetten et al. Annual Review of Pharmacology and Toxicology
- Retinoic acid receptor-related orphan receptor gamma-t (RORγt) inhibitors in clinical development for the treatment of autoimmune diseases: a patent review (2016-present)
- (2019) Nannan Sun et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Identification and biological evaluation of thiazole-based inverse agonists of RORγt
- (2018) Christian Gege et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Atul Deodhar et al. LANCET
- RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients
- (2018) Koen Venken et al. Nature Communications
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- (2017) Peter Nash et al. LANCET
- The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases
- (2017) Taku Kuwabara et al. MEDIATORS OF INFLAMMATION
- Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo
- (2017) Ulf Guendisch et al. PLoS One
- Characterization of a new pathway that activates lumisterol in vivo to biologically active hydroxylumisterols
- (2017) Andrzej T. Slominski et al. Scientific Reports
- Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma
- (2016) Ana L. Gomes et al. CANCER CELL
- Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis
- (2016) Xiaohua Xue et al. Scientific Reports
- Th17-biased RORγt transgenic mice become susceptible to a viral model for multiple sclerosis
- (2015) Nicholas E. Martinez et al. BRAIN BEHAVIOR AND IMMUNITY
- Identification of Natural RORγ Ligands that Regulate the Development of Lymphoid Cells
- (2015) Fabio R. Santori et al. Cell Metabolism
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Erratum: Corrigendum: Sterol metabolism controls TH17 differentiation by generating endogenous RORγ agonists
- (2015) Xiao Hu et al. Nature Chemical Biology
- Inflammation induces dermal Vγ4+γδT17 memory-like cells that travel to distant skin and accelerate secondary IL-17–driven responses
- (2015) Francisco Ramírez-Valle et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
- (2014) Christopher Ritchlin et al. ANNALS OF THE RHEUMATIC DISEASES
- RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D
- (2014) Andrzej T. Slominski et al. FASEB JOURNAL
- IL-17+ Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells
- (2014) Ruijuan Du et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Modulators of the Nuclear Receptor Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc)
- (2014) Benjamin P. Fauber et al. JOURNAL OF MEDICINAL CHEMISTRY
- Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
- (2014) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oxysterols are agonist ligands of ROR t and drive Th17 cell differentiation
- (2014) P. Soroosh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- (2013) Iain B McInnes et al. LANCET
- Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells
- (2013) You Jeong Lee et al. NATURE IMMUNOLOGY
- Pharmacologic Repression of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γ Is Therapeutic in the Collagen-Induced Arthritis Experimental Model
- (2013) Mi Ra Chang et al. Arthritis & Rheumatology
- Innate Lymphoid Cells: Emerging Insights in Development, Lineage Relationships, and Function
- (2012) Hergen Spits et al. Annual Review of Immunology
- Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- IL-17-producing γδ T cells and innate lymphoid cells
- (2012) Caroline E. Sutton et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial
- (2012) Kim A. Papp et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
- (2012) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
- (2012) Craig Leonardi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility
- (2010) Yuta Kochi et al. NATURE GENETICS
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
- (2010) W. Hueber et al. Science Translational Medicine
- NOD2/CARD15,ATG16L1andIL23Rgene polymorphisms and childhood-onset of Crohn’s disease
- (2010) Maria Gazouli WORLD JOURNAL OF GASTROENTEROLOGY
- Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
- (2009) E. Safrany et al. CURRENT MEDICINAL CHEMISTRY
- Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity
- (2009) H.-R. Yen et al. JOURNAL OF IMMUNOLOGY
- Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
- (2009) L. van der Fits et al. JOURNAL OF IMMUNOLOGY
- Association of interleukin-23 receptor variants with ankylosing spondylitis
- (2008) Proton Rahman et al. ARTHRITIS AND RHEUMATISM
- RORγ-Expressing Th17 Cells Induce Murine Chronic Intestinal Inflammation via Redundant Effects of IL-17A and IL-17F
- (2008) Moritz Leppkes et al. GASTROENTEROLOGY
- IL23R: a susceptibility locus for celiac disease and multiple sclerosis?
- (2008) C Núñez et al. GENES AND IMMUNITY
- Foxp3 Inhibits RORγt-mediatedIL-17AmRNA Transcription through Direct Interaction with RORγt
- (2008) Kenji Ichiyama et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function
- (2008) Liang Zhou et al. NATURE
- Influence of the transcription factor RORγt on the development of NKp46+ cell populations in gut and skin
- (2008) Carmelo Luci et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started